Posted On: 01/21/2015 1:12:38 AM
Post# of 30066
That's funny Maui, I was just wondering what's Eylea? and looked up this sales data...
Quote:
NEW YORK (TheStreet) -- Regeneron Pharmaceuticals Inc. (REGN - Get Report) shares are falling, down 5.2% to $374.53 in market trading on Tuesday, after the biopharmaceutical company lowered the top line of the full year forecast for its breakthrough macular degeneration drug treatment, Eylea.
The company now expects full year sales of Eylea to be in the $1.7 billion to $1.74 billion range, below its previous forecast of revenue of between $1.7 billion and $1.8 billion.
The company also reported a significant drop in third quarter net profit to $79.7 million, or $2.52 cents on an adjusted basis, from $141.3 million last year. Analysts were expecting third quarter earnings of $2.57 for the period.
Despite the lowered full year Eylea revenue guidance, the drug did post a 23% rise in sales to $445 million during the quarter.
http://www.thestreet.com/story/12940213/1/reg...dance.html
(0)
(0)
